Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing (Q36141619)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing |
scientific article |
Statements
1 reference
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing (English)
1 reference
Thomas B Nutman
1 reference
Jamie Robyn
1 reference
Irina Maric
1 reference
Weiming Fu
1 reference
Laura Schmid
1 reference
Steven Lemery
1 reference
Pierre Noel
1 reference
Melissa A Law
1 reference
Marilyn Hartsell
1 reference
Cheryl Talar-Williams
1 reference
20 August 2007
1 reference
1 reference
3552-3556
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference